EMA Encourages Use of New Approach Methodologies to Reduce Animal Testing

EMA Encourages Use of New Approach Methodologies to Reduce Animal Testing

EMA is phasing out animal testing and is asking pharmaceutical companies to use new approach methodologies.

Collaboration aims to reduce animal use in drug safety testing

OASIS consortium is evaluating omics tools in cells, including Cell Painting and transcriptomics, to predict liver toxicity of potential new medicines and agrochemicals.

European Medicines Agency Plans to Phase Out Animal Testing in Drug Development

The European Medicines Agency (EMA) is urging pharmaceu […] The post European Medicines Agency Plans to Phase Out Animal Testing in Drug Development first appeared on GeneOnline News. The post European Medicines Agency Plans to Phase Out Animal Testing in Drug Development appeared first on GeneOnline News.

HMA-EMA -Third Report on the use of RWE - Fondazione Gianni Benzi Onlus

The Heads of Medicines Agencies (HMA), in collaboration with the European Medicines Agency (EMA), has released the third report on the integration of Real-World Evidence (RWE) in regulatory decision-making. From February 2024 to February 2025, the number of RWE studies grew by 47.5%, with improved feasibility thanks to the expansion of DARWIN EU®, now including 30 data partners across 16 countries and covering around 180 million patients. The st…